182 related articles for article (PubMed ID: 35962345)
21. Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
Economopoulou P; Spathis A; Kotsantis I; Maratou E; Anastasiou M; Moutafi MK; Kirkasiadou M; Pantazopoulos A; Giannakakou M; Edelstein DL; Sloane H; Fredebohm J; Jones FS; Kyriazoglou A; Gavrielatou N; Foukas P; Panayiotides I; Psyrri A
Oral Oncol; 2023 Apr; 139():106358. PubMed ID: 36871349
[TBL] [Abstract][Full Text] [Related]
22. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
[TBL] [Abstract][Full Text] [Related]
23. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.
Hedberg ML; Goh G; Chiosea SI; Bauman JE; Freilino ML; Zeng Y; Wang L; Diergaarde BB; Gooding WE; Lui VW; Herbst RS; Lifton RP; Grandis JR
J Clin Invest; 2016 Jan; 126(1):169-80. PubMed ID: 26619122
[TBL] [Abstract][Full Text] [Related]
24. Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
Maihoefer C; Schüttrumpf L; Macht C; Pflugradt U; Hess J; Schneider L; Woischke C; Walch A; Baumeister P; Kirchner T; Zitzelsberger H; Belka C; Ganswindt U
Radiat Oncol; 2018 Jul; 13(1):123. PubMed ID: 29970111
[TBL] [Abstract][Full Text] [Related]
25. Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma.
Chen TH; Pan YY; Lee TL; Wang LW; Tai SK; Chu PY; Lo WL; Wu CH; Yang MH; Chang PM
BMC Cancer; 2022 Dec; 22(1):1336. PubMed ID: 36539738
[TBL] [Abstract][Full Text] [Related]
26. Recurrent and second primary squamous cell carcinoma of the head and neck: when and how to reirradiate.
Strojan P; Corry J; Eisbruch A; Vermorken JB; Mendenhall WM; Lee AW; Haigentz M; Beitler JJ; de Bree R; Takes RP; Paleri V; Kelly CG; Genden EM; Bradford CR; Harrison LB; Rinaldo A; Ferlito A
Head Neck; 2015 Jan; 37(1):134-50. PubMed ID: 24481720
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
Cohen EEW; Licitra LF; Burtness B; Fayette J; Gauler T; Clement PM; Grau JJ; Del Campo JM; Mailliez A; Haddad RI; Vermorken JB; Tahara M; Guigay J; Geoffrois L; Merlano MC; Dupuis N; Krämer N; Cong XJ; Gibson N; Solca F; Ehrnrooth E; Machiels JH
Ann Oncol; 2017 Oct; 28(10):2526-2532. PubMed ID: 28961833
[TBL] [Abstract][Full Text] [Related]
28. A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes.
Foy JP; Bazire L; Ortiz-Cuaran S; Deneuve S; Kielbassa J; Thomas E; Viari A; Puisieux A; Goudot P; Bertolus C; Foray N; Kirova Y; Verrelle P; Saintigny P
BMC Med; 2017 Sep; 15(1):165. PubMed ID: 28859688
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
30. Biological predictors of radiosensitivity in head and neck squamous cell carcinoma.
Fiedler M; Weber F; Hautmann MG; Haubner F; Reichert TE; Klingelhöffer C; Schreml S; Meier JK; Hartmann A; Ettl T
Clin Oral Investig; 2018 Jan; 22(1):189-200. PubMed ID: 28315964
[TBL] [Abstract][Full Text] [Related]
31. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Chung CH; Lee JW; Slebos RJ; Howard JD; Perez J; Kang H; Fertig EJ; Considine M; Gilbert J; Murphy BA; Nallur S; Paranjape T; Jordan RC; Garcia J; Burtness B; Forastiere AA; Weidhaas JB
Ann Oncol; 2014 Nov; 25(11):2230-2236. PubMed ID: 25081901
[TBL] [Abstract][Full Text] [Related]
32. RPA3 is a potential marker of prognosis and radioresistance for nasopharyngeal carcinoma.
Qu C; Zhao Y; Feng G; Chen C; Tao Y; Zhou S; Liu S; Chang H; Zeng M; Xia Y
J Cell Mol Med; 2017 Nov; 21(11):2872-2883. PubMed ID: 28557284
[TBL] [Abstract][Full Text] [Related]
33. Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the head and neck are treatment dependent.
Zhong S; Nukui T; Buch S; Diergaarde B; Weissfeld LA; Grandis J; Romkes M; Weissfeld JL
Cancer Epidemiol Biomarkers Prev; 2011 Nov; 20(11):2429-37. PubMed ID: 21890746
[TBL] [Abstract][Full Text] [Related]
34. Evidence-based radiation oncology in head and neck squamous cell carcinoma.
Corvò R
Radiother Oncol; 2007 Oct; 85(1):156-70. PubMed ID: 17482300
[TBL] [Abstract][Full Text] [Related]
35. Combined modality treatment outcomes for head and neck cancer: comparison of postoperative radiation therapy at academic vs nonacademic medical centers.
George JR; Yom SS; Wang SJ
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1118-26. PubMed ID: 24051518
[TBL] [Abstract][Full Text] [Related]
36. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.
Skinner HD; Sandulache VC; Ow TJ; Meyn RE; Yordy JS; Beadle BM; Fitzgerald AL; Giri U; Ang KK; Myers JN
Clin Cancer Res; 2012 Jan; 18(1):290-300. PubMed ID: 22090360
[TBL] [Abstract][Full Text] [Related]
37. Germline variants in DNA repair genes are associated with young-onset head and neck cancer.
Cury SS; Miranda PM; Marchi FA; Canto LMD; Chulam TC; Petersen AH; Aagaard MM; Pinto CAL; Kowalski LP; Rogatto SR
Oral Oncol; 2021 Nov; 122():105545. PubMed ID: 34598035
[TBL] [Abstract][Full Text] [Related]
38. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
[TBL] [Abstract][Full Text] [Related]
39. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Weidhaas JB; Harris J; Schaue D; Chen AM; Chin R; Axelrod R; El-Naggar AK; Singh AK; Galloway TJ; Raben D; Wang D; Matthiesen C; Avizonis VN; Manon RR; Yumen O; Nguyen-Tan PF; Trotti A; Skinner H; Zhang Q; Ferris RL; Sidransky D; Chung CH
JAMA Oncol; 2017 Apr; 3(4):483-491. PubMed ID: 28006059
[TBL] [Abstract][Full Text] [Related]
40. Predicting acute severe toxicity for head and neck squamous cell carcinomas by combining dosimetry with a radiosensitivity biomarker: a pilot study.
Deneuve S; Bastogne T; Duclos M; Mirjolet C; Bois P; Bachmann P; Nokovitch L; Roux PE; Girodet D; Poupart M; Zrounba P; Claude L; Ferella L; Iacovelli NA; Foray N; Rancati T; Pereira S
Tumori; 2023 Apr; 109(2):173-185. PubMed ID: 35578746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]